Use of Roseomonas Species to Treat Eczematous (Atopic Dermatitis) Skin Disease

Atopic dermatitis, also known as eczema, is a chronic itchy skin disease that affects over 20% of infants and young children in industrialized nations and may persist into adulthood for up to 50% of these cases, making it one of the most common skin diseases in the US and other developed countries.

Scientists at NIAID have developed a method of treating or preventing atopic dermatitis via the topical application of selected probiotic strains of gram-negative Roseomonas mucosa bacteria. This approach avoids the exhausting treatment demands of standard therapies and has been shown to be beneficial in a preclinical mouse model of atopic dermatitis.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of eczema
  • May be formulated as a cream or ointment
  • Corticosteroid-free
  • Animal data available


Ian Myles (NIAID)  ➽ more inventions...

Sandip Datta (NIAID)  ➽ more inventions...

Intellectual Property:
US Application No. 62/324,762
PCT Application No. PCT/US2017/028133
US Application No. 15/939,066

Myles IA, et al. PMID 27478874

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of Roseomonas species to treat eczematous (atopic dermatitis) skin disease. For collaboration opportunities, please contact Dr. David Yang at 240-627-3413 or

Licensing Contact:
Po-Lung (David) Yang, Ph.D.
Phone: 301-496-2644

OTT Reference No: E-099-2016-0
Updated: Oct 27, 2016